Overview
BPC-157 — formally designated Body Protection Compound 157 (also commonly referenced in research literature as BPC157, bpc-157 peptide, or simply BPC 157) — is a synthetic pentadecapeptide composed of 15 amino acids. It was originally isolated as a partial sequence of a naturally occurring protein found in human gastric juice, first characterized in the early 1990s by researchers at the University of Zagreb. Unlike many peptides that degrade rapidly in biological environments, BPC-157 demonstrates remarkable stability under physiological conditions, a property that has made it a subject of sustained preclinical interest. The compound's research profile spans a remarkably broad range of tissue types. Preclinical investigations have examined its activity in tendon, ligament, muscle, bone, gastrointestinal mucosa, and vascular tissue. Its stability and apparent pleiotropic activity have po
Mechanism of Action
BPC-157 modulates angiogenic signaling pathways — specifically through upregulation of vascular endothelial growth factor receptor-2 (VEGFR2) activity. Angiogenesis, the formation of new blood vessels from pre-existing vasculature, is a critical prerequisite for tissue repair; without adequate vascular supply, healing is severely impaired. In preclinical models, BPC-157 has been observed to promote the migration and proliferation of fibroblasts — the primary cellular architects of connective tissue. It has also been shown to upregulate the expression of the early growth response gene-1 (Egr-1), a transcription factor that orchestrates the expression of multiple growth factors involved in wo
Research Evidence
- Promotes VEGFR2-mediated angiogenesis in preclinical wound models (McGuire et al., 2025)
- Stimulates fibroblast migration and tendon outgrowth in ex vivo explant studies (Sikiric et al., 2021)
- Upregulates Egr-1 transcription factor, driving growth factor expression cascade
- Demonstrates stability under physiological conditions due to high proline content
- Modulates nitric oxide signaling pathways in gastrointestinal and vascular tissue models
Bottom line: BPC-157 is one of the most extensively studied synthetic peptides in preclinical regenerative research. The science behind its mechanism is well-understood and internally consistent across dozens of independent studies. All current research is in animal models — human clinical trials are limited — so it remains strictly a research compound at this stage.
Research Protocols & Dosage
Evidence-based research protocols, administration routes, and dosage considerations for BPC-157 are detailed in the full compound profile. See also: Dosage guide for BPC-157.
Sourcing & Quality
BPC-157 is available from Purgo Labs with third-party COA verification and research-grade purity standards. View BPC-157 at Purgo Labs.